MGF

Synthetic 24-residue IGF-1Ec E-domain research peptide

≥ 99.0% · target, verify batch COACAS Confirm per batch COARUO
Batch COA
MOQ1 kit (10 vials) per SKU
Supplied formUnmodified linear 24-mer; termini and stabilization state confirmed per lot
Lead time14–21 days
MGF — Lot-specific lyophilized research peptide, commonly white to off-white; appearance is not an identity or sterility test
MGF — Lot-specific lyophilized research peptide, commonly white to off-white; appearance is not an identity or sterility test · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • Research applications include testing the proposed activity of the isolated E-domain sequence, comparing positive and negative myoblast findings, evaluating sequence or stabilization effects, and distinguishing IGF-1Ec transcript biology from mature IGF-1 signaling
  • These are research questions, not established muscle-repair or anti-ageing benefits.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
Confirm per batch COA
Formula
C121H199N41O40
Molecular weight
2868.17 g/mol
Appearance
Lot-specific lyophilized research peptide, commonly white to off-white; appearance is not an identity or sterility test
Purity
≥ 99.0% · target, verify batch COA
Storage
Follow the released-lot label and stability statement. Keep lyophilized material sealed and protected from moisture; qualify reconstituted concentration, solvent, pH, container, temperature and hold time. Avoid repeated freeze-thaw unless supported by lot-specific data.
MOQ
1 kit (10 vials) per SKU
Lead time
14–21 days

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about MGF

This product is a synthetic 24-residue peptide corresponding to the unique C-terminal region of the human IGF-1Ec E domain. The term MGF is also used for the load-responsive IGF-1Ec transcript or propeptide. Peer-reviewed literature has not established that an identical free 24-mer is cleaved and released endogenously, so transcript expression and effects of an added synthetic peptide must be described separately.

  • IGF-1 splice-transcript research; synthetic E-domain peptide activity assays; myoblast and progenitor-cell models; structure-activity or stabilization studies; analytical differentiation of unmodified and PEGylated material.

Mechanism context

The question the literature is testing

Some studies report synthetic MGF-24aa-E effects in cell or animal models and propose signaling distinct from canonical IGF-1R. Other well-controlled work found no apparent myoblast or primary muscle-stem-cell activity. The receptor, endogenous processing and physiological relevance of the free 24-mer remain unresolved.

Evidence map

Research routes and exposure context

Evidence tierMixed evidence context
Routes reported in sources
No administration route applies
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • Research Use Only; not an approved finished drug and not for human or veterinary use
  • Human safety is not established
  • WADA lists mechano growth factors in S2.3, prohibited at all times for athletes subject to the Code
  • Handle according to the SDS and institutional risk assessment.

Interactions reported in the literature

  • For experiments, control mature IGF-1, serum proteins, peptide concentration, modification state, cell source and assay timing
  • No clinical stack, insulin, GH-axis or other peptide-combination guidance is provided.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

MGF batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

  • Blurred preview of a MGF 2 mg batch COA2 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

  • Require exact sequence and termini, modification status, RP-HPLC purity with method, intact mass, LC-MS/MS sequence confirmation where available, peptide content, counterion, water and residual solvents
  • Appearance or clear reconstitution cannot prove identity, activity, sterility or human suitability.
Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
MGF22 mg10 vials

Handling

Plan storage before the parcel arrives

Follow the released-lot label and stability statement. Keep lyophilized material sealed and protected from moisture; qualify reconstituted concentration, solvent, pH, container, temperature and hold time. Avoid repeated freeze-thaw unless supported by lot-specific data.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • Core evidence includes PMID 20130113, 16024511, 19567392, 17581790, 21354439, 24253050, 24146828 and 23125840. Anti-doping status is verified against WADA S2.3. Positive and negative experimental findings must be interpreted together.
  1. 01

    Mechanical Signals, IGF-I Gene Splicing, and Muscle Adaptation

    Physiology (Bethesda) [American Physiological Society] · 2005 · peer-reviewed review article (foundational)

    Open source
  2. 02

    Expression of IGF-1 Isoforms after Exercise-induced Muscle Damage in Humans: Characterization of the MGF E Peptide Actions In Vitro

    In Vivo · 2009 · peer-reviewed original research (human + in vitro)

    Open source
  3. 03

    Mechano-growth Factor Reduces Loss of Cardiac Function in Acute Myocardial Infarction

    Heart, Lung and Circulation · 2008 · peer-reviewed original research (large-animal preclinical, sheep model)

    Open source
  4. 04

    Mechano Growth Factor E Peptide (MGF-E), Derived from an Isoform of IGF-1, Activates Human Muscle Progenitor Cells and Induces an Increase in Their Fusion Potential at Different Ages

    Mechanisms of Ageing and Development · 2011 · peer-reviewed original research (human primary cell culture)

    Open source
  5. 05

    Mechano-growth Factor Peptide, the COOH Terminus of Unprocessed Insulin-like Growth Factor 1, Has No Apparent Effect on Myoblasts or Primary Muscle Stem Cells

    American Journal of Physiology-Endocrinology and Metabolism · 2014 · peer-reviewed original research (contradictory/refutation study)

    Open source
  6. 06

    Insulin-Like Growth Factor I (IGF-1) Ec/Mechano Growth Factor – A Splice Variant of IGF-1 within the Growth Plate

    PLoS One · 2013 · peer-reviewed original research (piglet growth plate model)

    Open source
  7. 07

    Mechano-Growth Factor: An Important Cog or a Loose Screw in the Repair Machinery?

    Frontiers in Endocrinology · 2012 · peer-reviewed review/opinion article

    Open source
  8. 08

    The Prohibited List (2026) — S2.3 Growth Factors and Growth Factor Modulators

    World Anti-Doping Agency (official regulatory body) · 2026 · regulatory/anti-doping body official document

    Open source

Product FAQ

Questions buyers ask about MGF

What does “MGF” identify on this page?+

Here it identifies a synthetic 24-residue peptide, YQPPSTNKNTKSQRRKGSTFEEHK, corresponding to the unique C-terminal region of the human IGF-1Ec E domain. In biology papers, MGF can instead mean the IGF-1Ec transcript or full propeptide. Mature 70-residue IGF-1 is shared by the isoforms, and IGF-1 LR3 is an engineered receptor agonist. These materials and evidence types are not interchangeable.

Has the same free 24-residue peptide been proven to exist endogenously?+

Not conclusively. A peer-reviewed minireview found no demonstrated processing step that releases the proposed 24-mer from pro-IGF-1Ec. Studies of IGF-1Ec mRNA therefore show splice-variant expression, not necessarily production of a free MGF-24aa-E peptide. Likewise, effects after adding a synthetic peptide establish only that intervention in that model.

Evidence before order

Buyer intelligence